Emergent BioSolutions, which ruined 75 million Johnson & Johnson vaccine doses at its Baltimore plant, disclosed record requests from Congress and federal and state law enforcement agencies.,

Advertisement

Continue reading the main story

The U.S. authorities are seeking documents from a troubled Covid vaccine manufacturer

Robert Kramer, the chief executive of Emergent, spoke via videoconference in May during a House panel hearing.Credit…Stefani Reynolds for The New York Times

July 30, 2021, 2:34 p.m. ET

The Maryland manufacturer that ruined 75 million doses of Johnson & Johnson’s Covid-19 vaccine has received requests to hand over records from a host of federal and state law enforcement agencies, regulatory documents filed Friday show.

The company, Emergent BioSolutions, disclosed that it had received “preliminary inquiries and subpoenas to produce documents” from the Justice Department, the Securities and Exchange Commission, the Financial Industry Regulatory Authority, the attorneys general of Maryland and New York and committees in both houses of Congress.

The disclosure suggests broadening scrutiny of the politically connected company, which received a $628 million federal contract to be the primary domestic manufacturer of the Johnson & Johnson and AstraZeneca vaccines. Production at a company facility in Baltimore was halted for more than three months after a batch of Johnson & Johnson’s vaccine was found to be contaminated and a subsequent inspection by regulators uncovered serious quality-control problems.

Emergent is already facing a congressional investigation and multiple shareholder lawsuits related to its manufacturing problems. In its disclosure on Friday, the company provided no further detail on the previously unknown requests, but said it was “producing and has produced documents as required in response and will continue to cooperate with these government inquiries.”

Officials with the state and federal agencies, as well as an Emergent spokesman, did not immediately respond to requests for comment Friday.

The disclosure, previously reported by Reuters, comes a day after Emergent announced that the Food and Drug Administration had given the go-ahead to resume manufacturing at the Baltimore site, which had been shuttered since April as the company worked to address deficiencies cited by inspectors.

The agency’s decision does not mean that it has broadly authorized Johnson & Johnson to distribute doses made by Emergent on an emergency basis. The F.D.A. signed off on previous batches of vaccine made at the Baltimore factory but with a warning that the agency could not guarantee that the company had followed good manufacturing practices.

In a conference call with investors on Thursday, Emergent executives announced a $41.5 million hit from being forced to discard vaccine doses deemed unusable by the F.D.A., and said the company had spent another $12.4 million to address manufacturing problems at the Baltimore site.

The newly disclosed inquiries from federal and state agencies underscore a dramatic reversal of fortune for a company that had spent much of the last two decades effectively cornering the market for biodefense, becoming the government’s go-to contractor for products to protect against infectious disease outbreaks and terrorist attacks with bioweapons.

When the coronavirus pandemic hit, the government turned to Emergent to produce vaccines and treatments. Thanks to a lucrative deal struck in May 2020, Emergent recorded record profits and awarded executives record bonuses.